Spain to invest E105M in drug-use campaign

9 January 2006

As it scrambles to cut a rising prescriptions bill, Spain's Health Ministry has announced it will spend 105.0 million euros ($125.9 million) to educate health professionals on rationalizing drug use.

The Ministry, led by Elena Salgado, will launch initiatives to inform doctors and pharmacists about the rational use of a range of drugs. The effort will also feature smaller activities to inform the public about how to pace their consumption of medicines.

The campaign follows two advertising initiatives aimed at educating Spanish people about drugs. The last such undertaking finished in November 2005 and this informed the public about generic medicines. Another campaign, explaining the ill-effects of auto-medication, ran earlier in the fall. The Spanish drug regulatory agency, Agencia Espanola de Medicamentos y Productos Sanitarios, will undertake the new information campaign, which will reach the country's 17 regions.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight